Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease with distinct biological
and clinical features. The biologic basis of the stereotypical progression from chronic phase …

Chronic myeloid leukemia (CML) is characterized by the clonal expansion of hematopoietic
stem cells (HSCs). Without effective treatment, individuals in the indolent, chronic phase …

The tyrosine kinase inhibitor imatinib mesylate (Gleevec)(formerly STI571) has proven to be
an effective and safe new therapy for patients with chronic myeloid leukemia (CML). It has …

Currently, limited molecular markers exist that can determine where in the spectrum of
chronic myeloid leukemia (CML) progression an individual patient falls at diagnosis. Gene …

Chronic myeloid leukemia (CML) is the prototype cytogenetic malignancy. Even before the
development of basic G-and R-banding techniques, CML was found to be associated with a …

Although most patients with chronic myeloid leukemia (CML) have the same initial molecular
abnormality, the BCR-ABL fusion gene, the duration of chronic phase (CP) varies widely. To …

An extraordinary series of discoveries about chronic myeloid leukemia (CML) has made this
disease a model of the way in which bench and bedside research can unite and culminate …

In the past decade clinical and laboratory studies have led to important new insights into the
biology of chronic myeloid leukemia (CML). Basic science has defined the molecular …

Blast crisis (BC) predicts dismal outcomes in patients with chronic myeloid leukaemia (CML).
Although additional genetic alterations play a central role in BC, the landscape and …

Despite recent advances in our understanding of the molecular and biological abnormalities
in chronic myelogenous leukemia (CML) this new knowledge has not yet led to significant …